Alkindi Sprinkle Patent Expiration

Alkindi Sprinkle is a drug owned by Eton Pharmaceuticals Inc. It is protected by 3 US drug patents filed in 2021 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 12, 2034. Details of Alkindi Sprinkle's patents and their expiration are given in the table below.


Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9717740 Treatment of adrenal insufficiency
Nov, 2032

(8 years from now)

Active
US9675559 Treatment of adrenal insufficiency
Jan, 2033

(8 years from now)

Active
US9649280 Composition comprising hydrocortisone
May, 2034

(9 years from now)

Active

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Alkindi Sprinkle is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Alkindi Sprinkle's family patents as well as insights into ongoing legal events on those patents.

Alkindi Sprinkle's family patents

Alkindi Sprinkle has patent protection in a total of 24 countries. It's US patent count contributes only to 6.0% of its total global patent coverage. Click below to unlock the full patent family tree for Alkindi Sprinkle.

Family Patents

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳



Generic Launch

Generic Release Date:

Alkindi Sprinkle's generic launch date based on the expiry of its last outstanding patent is estimated to be May 12, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Alkindi Sprinkle Generics:

Hydrocortisone is the generic name for the brand Alkindi Sprinkle. 68 different companies have already filed for the generic of Alkindi Sprinkle, with Taro having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Alkindi Sprinkle's generic





About Alkindi Sprinkle

Alkindi Sprinkle is a drug owned by Eton Pharmaceuticals Inc. It is used for treating adrenal insufficiency. Alkindi Sprinkle uses Hydrocortisone as an active ingredient. Alkindi Sprinkle was launched by Eton in 2020.

Market Authorisation Date:

Alkindi Sprinkle was approved by FDA for market use on 29 September, 2020.

Active Ingredient:

Alkindi Sprinkle uses Hydrocortisone as the active ingredient. Check out other Drugs and Companies using Hydrocortisone ingredient

Treatment:

Alkindi Sprinkle is used for treating adrenal insufficiency.

Dosage:

Alkindi Sprinkle is available in granule form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.5MG GRANULE Prescription ORAL
1MG GRANULE Prescription ORAL
2MG GRANULE Prescription ORAL
5MG GRANULE Prescription ORAL